Information:
Fel:
ID
39315
Beskrivning
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01303679
Länk
https://clinicaltrials.gov/show/NCT01303679
Nyckelord
Versioner (1)
- 2019-12-18 2019-12-18 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
18 december 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility First Line Metastatic Breast Cancer NCT01303679
Eligibility First Line Metastatic Breast Cancer NCT01303679
- StudyEvent: Eligibility
Similar models
Eligibility First Line Metastatic Breast Cancer NCT01303679
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Age
Item
age > 18 ans.
boolean
C0001779 (UMLS CUI [1])
Secondary malignant neoplasm of female breast | Locally advanced breast cancer
Item
metastatic breast cancer or locally advanced
boolean
C0346993 (UMLS CUI [1])
C3495949 (UMLS CUI [2])
C3495949 (UMLS CUI [2])
Estrogen receptor positive | HER2 Negative
Item
re+, her2-
boolean
C0279754 (UMLS CUI [1])
C2348908 (UMLS CUI [2])
C2348908 (UMLS CUI [2])
Chemotherapeutics regimen first line of treatment | Paclitaxel | bevacizumab
Item
patient receiving paclitaxel-bevacizumab first line chemotherapy
boolean
C2045825 (UMLS CUI [1])
C0144576 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
C0144576 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
Prior Adjuvant Therapy | exemestane | Prior Therapy metastatic
Item
previous treatment by exemestane (both in adjuvant or metastatic treatment).
boolean
C1514456 (UMLS CUI [1])
C0851344 (UMLS CUI [2])
C1514463 (UMLS CUI [3,1])
C1522484 (UMLS CUI [3,2])
C0851344 (UMLS CUI [2])
C1514463 (UMLS CUI [3,1])
C1522484 (UMLS CUI [3,2])
Cemotherapeutics regimen first line of treatment | Except Paclitaxel | Except Bevacizumab
Item
1st line of chemotherapy different thaan paclitaxel-bevacizumab.
boolean
C2045825 (UMLS CUI [1])
C0332300 (UMLS CUI [2,1])
C0144576 (UMLS CUI [2,2])
C0332300 (UMLS CUI [3,1])
C0796392 (UMLS CUI [3,2])
C0332300 (UMLS CUI [2,1])
C0144576 (UMLS CUI [2,2])
C0332300 (UMLS CUI [3,1])
C0796392 (UMLS CUI [3,2])
Prior Therapy | Paclitaxel | bevacizumab
Item
treatment by paclitaxel-bevacizumab > 18 weeks.
boolean
C1514463 (UMLS CUI [1])
C0144576 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
C0144576 (UMLS CUI [2])
C0796392 (UMLS CUI [3])
HER2 Positive | Estrogen receptor negative
Item
her2 positifs et/ou récepteurs aux oestrogènes négatifs.
boolean
C2348909 (UMLS CUI [1])
C0279756 (UMLS CUI [2])
C0279756 (UMLS CUI [2])
Thrombosis Event Previous
Item
previous thrombosis event within the 6 months before inclusion .
boolean
C0040053 (UMLS CUI [1,1])
C0441471 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
C0441471 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
Prior surgery
Item
previous significant surgery within the 28 days before treatment start
boolean
C0455610 (UMLS CUI [1])
Blood Coagulation Disorder Previous
Item
previuous coagulopathy.
boolean
C0005779 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,2])